Over the past five years, the cosmetic industry has met with several legislative changes. Within the new legislative package, including the new REACH and CLP, it is important to find a comfortable routine that will minimize costs while staying effective and compliant with all regulations.
A New Chairman at the ISO IDMP Implementation online conference
Timm Pauli has officialy become our new chairman for the ISO IDMP Implementation online conference. He will be keeping an eye towards its smooth execution and will add a great sense of professionalism to the event as his background speaks for himself.
A chairman, as the highest authority at an event, brings his opening speech and introduces each speaker. During the whole event he opens the Q&A sessions after speakers' presentations and gives a little feedback or poses questions at the end. Perhaps the biggest input is the chairman's final remarks, which have the power to sum things up, underline what was important and emphasize what things the attendees will walk away with.
Timm is Head of Regulatory Operations at Pharmalex Germany, where is responsible for all electronic submission activities, regulatory information management and related topics. He has already spoken at three of our online conferences:
- eCTD Submission Updates, Oct. 15, 2014
- eSubmission Updates 2015, Jun 17, 2015
- Generics: EU Regulatory Landscape, Oct 20, 2015
So we asked Timm, what his experiences have been with our events:
What would you highlight as interesting features included in these online conferences?
Fleming. online conferences offer simple yet high-quality access to hot topics within the domain of Regulatory Affairs and allow easy exchange with key experts. The conferences are well-prepared and professionally executed.
According to your experience, what kind of practical information can attendees usually take from them?
Those conferences I participated in the past focused on current developments as well as new and changed requirements in the context of Regulatory Affairs or Regulatory Operations. In most cases there is a good mixture of sharing theoretical background and practical experiences.
Do you consider your interaction with our delegates and speakers as a useful for you as well?
Even during the preparation, normally there are already good discussions with other speakers and contributors. And also during the event itself I am always excited about the good questions and feedback from participants, which make the events interesting and interactive sessions.
Interested in this topic?
Advanced Protein Aggregation & Characterization
This training will focus on occurrence of particles in drug products, effects of protein aggregates, critical process and parameters. Attendees will gain overview of on utility and limits of predictive experiments, learn concerns from the authorities and relevant aggregation guidelines, and more.
CMC Analytical Comparability: Methods & Strategies for Biologics, Biosimilars & Biobetters
Attendees will be introduced to comparability in biosimilar development, the analytical strategies of protein characterization of biosimilars, the structure of proteins, in vitro pharmacology and much more.
Corporate Compliance & Transparency in the Pharmaceutical Industry
This two-day conference will serve as a platform for an open and dynamic dialogue with HCPs and patients to achieve common goals. Learn how to embed compliance in the business and develop one simple system for managing compliance & transparency in a complex and regulated environment.
Driving the national agenda of Medical tourism through PX Excellence
Read the interview with Dr. Layla Al-Marzouqi, Director of Medical Tourism Council at Dubai Health Authority, and learn how to enrich patient experience and quality of healthcare.
No more trouble with dangerous good shipments
Global temperature controlled pharmaceutical shipments are constantly faced with new logistics challenges and regulations. This January 2017, IATA Dangerous Goods Regulations added further complexity to shipping cold chain products compliantly.
5 Changes in Signal Detection Management
The European Medicines Agency, regulatory authorities in the Member States and marketing authorisation holders are responsible for detecting and managing safety signals. A safety signal is generally defined as information about a new or known Adverse Event that may have been caused by a medicine, where it is therefore necessary to conduct further investigation. Evaluation of safety signals plays a major role within pharmacovigilance. Therefore, it is vital for regulatory authorities to know the latest updates detailing the risks and benefits of medicines. The EudraVigilance database is an important source of information on suspected adverse reactions and signals.